<DOC>
	<DOCNO>NCT00359840</DOCNO>
	<brief_summary>To assess clinical effective dose KRN321 administer triweekly schedule .</brief_summary>
	<brief_title>A Dose Finding Study KRN321 ( Darbepoetin Alfa ) Treatment Anemia Subjects With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>patient diagnose solid tumor malignant lymphoma patient receive cyclic chemotherapy write informed consent hemoglobin concentration 11 d/dL enrollment life expectancy 4 month hemolysis , gastrointestinal bleeding , postoperative bleeding iron deficiency megaloblastic anemia receive &gt; 2 RBC transfusion within 4 week randomization RBC transfusion within 2 week randomization primary hematological disorder could cause anemia prior treatment KRN321 receive erythropoetin therapy within 8 week treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>darbepoetin alfa</keyword>
	<keyword>anemia</keyword>
	<keyword>cancer patient</keyword>
	<keyword>chemotherapy</keyword>
</DOC>